FAQ: Lantern Pharma's FDA Guidance and Pediatric Cancer Therapy Development
Summary
Lantern Pharma received FDA guidance for its investigational therapy LP-184/STAR-001 targeting pediatric brain cancers, setting the company on track to launch clinical trials in Q1 2026 while also advancing treatments for other cancers with promising patient responses.
What is the main focus of Lantern Pharma’s recent FDA meeting?
The Type C meeting with the FDA provided guidance on the regulatory pathway and trial design for LP-184/STAR-001, Lantern Pharma’s investigational therapy targeting pediatric central nervous system cancers including Atypical Teratoid Rhabdoid Tumor (ATRT).
When does Lantern Pharma plan to launch its pediatric cancer trial?
The company plans to launch the clinical trial for LP-184/STAR-001 in Q1 of 2026, following amendments to its investigational new drug (IND) submission based on FDA guidance.
What other types of cancer is Lantern Pharma targeting with its drug candidates?
In addition to pediatric brain cancers, Lantern Pharma is developing therapies for glioblastoma (GBM), triple-negative breast cancer, non-small cell lung cancer in non-smokers, non-Hodgkin’s lymphoma, and other tumors.
How does Lantern Pharma develop its cancer therapies?
The company uses its proprietary drug candidates along with a computational biology and machine learning platform to develop clinical trials targeting conditions with unmet medical needs.
What recent clinical success has Lantern Pharma achieved?
Two of the company’s current trials achieved a complete response in patients during the past quarter, demonstrating promising clinical outcomes.
What is the significance of the FDA guidance for Lantern Pharma?
The FDA guidance helps the company work through the regulatory pathway and design the trial effectively, positioning them to realize their clinical trial plans for the rare pediatric cancer therapy.
Where is Lantern Pharma based and what is its stock symbol?
Lantern Pharma is a Texas-based clinical-stage biotechnology company trading on NASDAQ under the symbol LTRN.
How can investors get the latest updates about Lantern Pharma?
The latest news and updates relating to LTRN are available in the company’s newsroom at https://ibn.fm/LTRN.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)
Article Control ID: 239658